Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateSector Deep DivesUploadPipelinePE CyclesBrainAboutHow We Research

Data updated weekly. Not financial advice.

sectoralpha · stock story
Hospitals/Medical Services →
Home›Stocks›Park Medi World Ltd
PARKHOSPSPark Medi World LtdHospitals/Medical Services
₹295

Park Medi World Ltd (PARKHOSPS) — share price & stock analysis

Profits have nearly doubled in two years.

STEADY GROWTH
STAGE 2 UPTREND
COMPOUNDERMARGINS EXPANDINGNO REAL DEBT
DEEP CYCLICALEXPANSION
₹12,757 Cr
Market cap
49.4×
P/E
16.7%
ROE
By Sector Alpha Research · machine-compiled from Screener.in data · Updated 1 July 2026 · Sources: Screener.in company page, NSE quote · Not investment advice
The 30-second answer

Park Medi World Ltd (PARKHOSPS) trades at ₹295 as of 1 July 2026. The machine reads this as steady growth: profits have nearly doubled in two years. the price is in Stage 2 — advancing, 22 weeks in; the business cycle reads DEEP CYCLICAL / EXPANSION. Fundamentals-momentum score: 90/100 (all improving).

Data as of 1 July 2026 · every number traces to its Screener source column · not investment advice.

Key numbers
Market cap
₹12,757 Cr
P/E
49.4×
ROE
16.7%
Book value / share
₹46.8
Revenue (FY26)
₹1,679 Cr
Profit after tax (FY26)
₹274 Cr
Weinstein stage
Stage 2 (22 weeks)
Data as of
1 July 2026
MOMENTUM OF THE FUNDAMENTALS
90/100
ALL IMPROVING
Levels: ROCE 19% — decent · effectively no debt · margins near the bottom of their band
SalesUp 30% YoY
MarginsOPM 25.0% → 27.7% in a year
ProfitUp 48% YoY
Cash generationOperating cash ₹191 Cr → ₹329 Cr
Balance sheetDebt is ₹18 per ₹100 of shareholders’ money
DEEP CYCLICAL
Trough
Recovery
Expansion
Peak

Profits swing violently in this business — margins swinging 15 points peak to trough. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.net_profit

Where the clock stands now: earnings sit at 100% of their historical range, margins are near the bottom of their band, and valuation history is thin. That reads as EXPANSION — the middle of the cycle with margins still near their own lows — if margins mean-revert upward there is fuel left; if they don’t, growth has to do all the work.net_profit

One tension to hold: profits are compounding while margins sit near the bottom of their own historical band. That cuts both ways — there is recovery left to collect if margins climb back, but it also means today’s growth is being earned on thin economics.

5 of the 5 things we track are currently moving the right way — nearly everything is pulling in the same direction.

Where the levels actually stand: ROCE 19% — decent; effectively no debt; margins near the bottom of their band. Momentum says which way things are moving; these say where they are.

Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double, and a quarter of the score comes from our earnings-recovery lens (is the profit cycle turning up off its trough?).

WHERE THE PRICE IS IN ITS CYCLE

The price is in a confirmed uptrend — 22 weeks and counting

STAGE 2 · ADVANCING · 22 WEEKS

Stock prices move through four repeating stages: basing (1), advancing (2), topping (3) and declining (4). This one is in Stage 2: advancing, 22 weeks in, confirmed.stage

The price sits above its rising 200-day average (₹205 today) — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200

What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200

Weekly price with its 200-day and 50-day averages — stages shaded₹weinstein_stages
S2150200250300Price200-DMAStage 2 began · Feb 26Dec 25Mar 26Jun 26Jul 26
Data: Weekly price, moving averages and stage
PeriodPrice (₹)200-DMA (₹)50-DMA (₹)Stage
Dec 251551481494
Dec 251461481484
Jan 261501481484
Jan 261491481484
Jan 261511481491
Jan 261561491501
Feb 261511491501
Feb 261531491511
Feb 261761501541
Feb 261841511592
Feb 261931531652
Mar 262031551692
Mar 261931571752
Mar 261991591782
Mar 262001611812
Apr 261971621832
Apr 262101641872
Apr 262171651902
Apr 262331681972
Apr 262311712022
May 262501752102
May 262451782172
May 262591822242
May 262891862332
Jun 262861902402
Jun 262821912422
Jun 262931932452
Jun 262801932472
Jun 262751952492
Jun 262541972512
Jun 262781982522
Jun 262882012562
Jun 262862022572
Jul 262952052612
THE LONG ARC

Profits have grown in 4 of the last 5 years — compounding so far, on a short record

Over 5 years, sales went from ₹766 Cr to ₹1,679 Cr (about 17% a year), and profit from ₹187 Cr to ₹274 Cr.revenuenet_profit

Margins gave up 13.9 points along the way — growth bought at a price.operating_profit

Revenue by year₹ Crannual_results
01,000FY21FY23FY25FY26
Data: Revenue by year
PeriodRevenue (₹ Cr)
FY21766
FY221,084
FY231,255
FY241,231
FY251,394
FY261,679
Profit by year₹ Crannual_results
0100200FY21FY23FY25FY26
Data: Profit by year
PeriodProfit after tax (₹ Cr)
FY21187
FY22199
FY23228
FY24152
FY25213
FY26274
OPM % by year%annual_results
25.030.035.040.0FY21FY23FY25FY26
Data: OPM % by year
PeriodOPM % (%)
FY2140.3
FY2231.8
FY2331.2
FY2425.3
FY2526.9
FY2626.4
CHAPTER 1 · THE ENGINE

Sales jumped 30% last quarter

Revenue — the money that comes in from customers, before any costs.

Mar 26 sales were ₹460 Cr, up 30% on the same quarter last year.revenue

Quarterly sales₹ Crquarterly_results
0200400YoY %+30Dec 24Sep 25Mar 26
Data: Quarterly sales
PeriodRevenue (₹ Cr)YoY growth (%)
Dec 24348–
Mar 25354–
Sep 25410–
Dec 2541017.8
Mar 2646029.9
WATCH →If quarterly growth slips below 15%, the story weakens.
CHAPTER 2 · THE TAKE

Margins are widening — 25% → 28% in a year

Margins — the share of every ₹100 of sales kept as profit. Gross (after raw materials), operating (after running costs), net (after everything).

Of every ₹100 of sales, the company keeps ₹27.7 as operating profit (a year ago it kept ₹25.0).opm_pct

The gross margin barely moved (82% → 83%), so the change came from running costs — the business is getting more efficient as it scales.gpm_pctopm_pct

Three margins, quarterly%margin_trends
20.040.060.080.0GrossOperatingNetSep 24Mar 25Dec 25Mar 26
Data: Three margins, quarterly
PeriodGross (%)Operating (%)Net (%)
Sep 2478.527.416.3
Dec 2479.223.813.1
Mar 2582.325.014.8
Sep 2582.827.519.1
Dec 2581.624.312.9
Mar 2682.727.716.7
WATCH →Two consecutive quarters of margin decline would break this trend.
CHAPTER 3 · THE BOTTOM LINE

Profit exploded 48% — mostly from selling more

PAT (profit after tax) — what is left for shareholders after every cost, interest and tax.

Mar 26 profit after tax was ₹77.0 Cr, up 48% year on year.net_profit

Quarterly profit after tax₹ Crquarterly_results
025.050.075.0YoY %+48Dec 24Sep 25Mar 26
Data: Quarterly profit after tax
PeriodPAT (₹ Cr)YoY growth (%)
Dec 2446.0–
Mar 2552.0–
Sep 2579.0–
Dec 2553.015.2
Mar 2677.048.1
Where the profit change came from (Mar 25 → Mar 26)₹ Cr
52+26+13−1−2+2−12−177PAT Mar 25More salesFattermarginsOther incomeDepreciationInterestTaxEverythingelsePAT Mar 26

The single biggest driver was selling more.

Data: Where the profit change came from (Mar 25 → Mar 26)
ComponentEffect (₹ Cr)
PAT Mar 2552
More sales+26
Fatter margins+13
Other income−1
Depreciation−2
Interest+2
Tax−12
Everything else−1
PAT Mar 2677
CHAPTER 4 · THE ACID TEST

The profits are real — they turn into cash

Operating cash flow (CFO) — the cash that actually arrived, vs PAT, the profit accounting reports. Annual figures.

Over the last 5 profitable years, the business reported ₹1,066 Cr of profit and collected ₹1,235 Cr of operating cash — about 116% conversion.operating_cash_flownet_profit

When cash tracks profit this closely, the earnings need no asterisk.

Cash collected vs profit reported (annual)₹ Crcash_flow
200300Operating cash flowProfit after taxFY21FY23FY25FY26
Data: Cash collected vs profit reported (annual)
PeriodOperating cash flow (₹ Cr)Profit after tax (₹ Cr)
FY21223187
FY22155199
FY23199228
FY24361152
FY25191213
FY26329274
CHAPTER 5 · THE PIPELINE

The cash cycle is tightening — money comes home faster

Working capital — days of sales locked up in inventory and unpaid bills. Screener reports this yearly, so this chart is annual.

One rupee now takes about -2 days to go out the door as materials and come back as collected cash — down from 161 days the year before.cash_conversion_cycle

The biggest mover: customers paying faster (161 → 129 days).debtor_days

Days of cash locked up (annual)daysratios
050100150Customers owe (debtor days)Stock on shelf (inventory days)We owe suppliers (payable days)FY21FY23FY25FY26
Data: Days of cash locked up (annual)
PeriodCustomers owe (debtor days) (days)Stock on shelf (inventory days) (days)We owe suppliers (payable days) (days)
FY2115147.0121
FY2215114.0101
FY231683.0110
FY24151––
FY25161––
FY261294.0134
CHAPTER 6 · THE BUILD

The asset base keeps compounding — this company builds

Capex — money spent on plants, machines and buildings. Gross block is what exists; CWIP (capital work-in-progress) is what is being built. Annual.

The productive asset base has gone from ₹365 Cr (FY21) to ₹1,309 Cr, with another ₹123 Cr of capacity under construction right now.fixed_assetscwip

The build is self-funded: the last 3 years' investing outflow (₹679 Cr) fits inside the operating cash the business generated (₹881 Cr).investing_cash_flowoperating_cash_flow

Assets in place vs under construction (annual)₹ Crbalance_sheet
05001,000Fixed assetsUnder construction (CWIP)FY21FY23FY25FY26
Data: Assets in place vs under construction (annual)
PeriodFixed assets (₹ Cr)Under construction (CWIP) (₹ Cr)
FY213657.0
FY2245829.0
FY235365.0
FY2483732.0
FY2589837.0
FY261,309123
CHAPTER 7 · SURVIVAL

Almost no debt — this company cannot be killed by a bad year

Debt-to-equity — borrowings against shareholders’ money. Computed from the balance sheet. Annual.

For every ₹100 shareholders have put in (and left in), the company has borrowed ₹18.borrowings

Total borrowings (annual)₹ Crbalance_sheet
0250500FY21FY23FY25FY26
Data: Total borrowings (annual)
PeriodBorrowings (₹ Cr)
FY21292
FY22517
FY23576
FY24687
FY25682
FY26364
Debt vs shareholders’ money (annual)xbalance_sheet
00.51FY21FY23FY25FY26
Data: Debt vs shareholders’ money (annual)
PeriodDebt ÷ equity (x)
FY211.1
FY221.1
FY230.8
FY240.8
FY250.6
FY260.2
CHAPTER 8 · THE ENGINE ROOM

Every ₹100 kept in the business earns ₹19 — decent, not special

ROCE — profit earned per ₹100 of capital used. ROE — the same, per ₹100 of shareholders’ money alone. Annual.

Return on capital employed is 19.0% (a year ago: 20.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct

Returns on capital (annual)%ratios
20.025.030.035.0ROCEFY22FY24FY26
Data: Returns on capital (annual)
PeriodROCE (%)
FY2238.0
FY2331.0
FY2420.0
FY2520.0
FY2619.0
THE VERDICT

Worth studying deeper — with eyes open

The numbers lean positive, and the price is roughly fair to the delivery so far.

Best thing in the data: cash generation rising (₹191 Cr → ₹329 Cr).operating_cash_flow

Biggest worry: free cash flow falling (₹100 Cr → ₹−4.0 Cr).operating_cash_flow

One dissent worth hearing: our valuation lens reads negative — “its fair-value math says the price sits about 30% above what the numbers justify”. When a lens disagrees with the committee, it is usually pointing at the thing that breaks first.

The machine committee — 7 independent readsSTUDY DEEPER · 78%
Earnings patternPOSITIVE60% · w21
Valuation cyclePOSITIVE70% · w19
CatalystsNEUTRAL40% · w14
Quality & safetyPOSITIVE58% · w14
TechnicalsPOSITIVE40% · w12
ValuationNEGATIVE65% · w10
Growth at a pricePOSITIVE52% · w10
One model disagrees — the Valuation lens reads this stock as NEGATIVE (65% confidence): “its fair-value math says the price sits about 30% above what the numbers justify”
Business quality7.4/10
Management5.8/10
7-model research readSTUDY DEEPER · 78% confidence
WHAT WOULD CHANGE THIS VIEWTwo quarters of margins reversing would kill this story.

Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.

More Hospitals/Medical Services stocks
Dr Agarwals Health Care LtdNephrocare Health Services LtdGujarat Kidney & Super Speciality LtdUnihealth Hospitals LtdGaudium IVF and Women Health LtdKRM Ayurveda LtdAll Hospitals/Medical Services stocks →
Frequently asked questions

Straight answers from the data

What does Park Medi World Ltd do?

Park Medi World engaged in the business of, inter alia, establishing, maintaining and running hospitals, nursing homes, clinics, dispensaries, maternity homes, child welfare, family planning etc.(Source : 202503 Annual Report Page No:320). It is listed in the Hospitals/Medical Services sector with a market capitalisation of ₹12,757 Cr.

What is Park Medi World Ltd's share price?

As of 1 July 2026, Park Medi World Ltd trades at ₹295, with a market capitalisation of ₹12,757 Cr. Prices are weekly closes from Screener data; this page refreshes with each weekly update.

What is Park Medi World Ltd's share price target?

Sector Alpha does not publish broker-style price targets. Our discounted-cash-flow model estimates Park Medi World Ltd's intrinsic value at ₹246 per share under base assumptions (bear ₹105, bull ₹337), against the current price of ₹295 — a 14% premium to model value. These are model estimates, not forecasts — treat them as one input alongside the valuation history below, not as a target.

What did Park Medi World Ltd report in its latest quarterly results?

In its most recent reported quarter (Q4 FY26, quarter ended March 2026): Mar 26 sales were ₹460 Cr, up 30% on the same quarter last year. Mar 26 profit after tax was ₹77.0 Cr, up 48% year on year. Figures are from Screener-scraped quarterly filings; the page updates when the next quarter is filed.

Is Park Medi World Ltd growing?

Sales jumped 30% last quarter. Mar 26 sales were ₹460 Cr, up 30% on the same quarter last year.

Are Park Medi World Ltd's profits growing?

Profit exploded 48% — mostly from selling more. Mar 26 profit after tax was ₹77.0 Cr, up 48% year on year.

What are Park Medi World Ltd's operating margins?

Margins are widening — 25% → 28% in a year. In the most recent quarter, of every ₹100 of sales, the company keeps ₹27.7 as operating profit (a year ago it kept ₹25.0).

What is Park Medi World Ltd's long-term growth record?

Revenue grew from ₹766 Cr in FY21 to ₹1,679 Cr in FY26 — a 17.0% compound annual growth rate over 5 years. Profit after tax compounded at 7.9% over the same period (₹187 Cr → ₹274 Cr).

Is Park Medi World Ltd stock in an uptrend?

The price is in a confirmed uptrend — 22 weeks and counting. Park Medi World Ltd is in Stage 2 — advancing, 22 weeks in (confirmed). Stages follow Stan Weinstein's four-phase read of weekly price against the 200-day average: basing (1), advancing (2), topping (3), declining (4).

Where is Park Medi World Ltd in its business cycle?

The data reads Park Medi World Ltd as a deep cyclical business currently in its expansion phase — earnings at an all-time high for this company. Profits swing violently in this business — margins swinging 15 points peak to trough. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.

Does Park Medi World Ltd have too much debt?

Almost no debt — this company cannot be killed by a bad year. For every ₹100 shareholders have put in (and left in), the company has borrowed ₹18.

What is the bull case for Park Medi World Ltd?

Profits have nearly doubled in two years. Best thing in the data: cash generation rising (₹191 Cr → ₹329 Cr). Sales jumped 30% last quarter.

What is the bear case for Park Medi World Ltd — what could break the story?

Biggest worry: free cash flow falling (₹100 Cr → ₹−4.0 Cr). Two quarters of margins reversing would kill this story. The nearest-term thing to watch: if quarterly growth slips below 15%, the story weakens. This falsification condition is stated up front so the thesis can be checked against incoming quarters, not defended after the fact.

Is Park Medi World Ltd a stock worth studying right now?

Sector Alpha does not publish buy or sell recommendations — this is a research read, not advice. What the data says: worth studying deeper — with eyes open. The numbers lean positive, and the price is roughly fair to the delivery so far. Across the 7-model scorecard the composite research signal is study deeper at 78% confidence. This is machine-written research compiled from Screener data — every number traces to its source — and it is not investment advice. Do your own diligence.

Generated from Screener data · 12 sources · why_traces/1.0 + story/1.2
details
generated 2026-07-03 11:21 · 6 material moves detected
sources: screener_company_info, screener_quarterly_results, screener_annual_results, screener_valuation_history, screener_shareholding, screener_cash_flow, screener_ratios, screener_balance_sheet, screener_margin_trends, weinstein_stages, agent_scores, stock_timelines